SCM
BMRN icon

Suffolk Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Suffolk Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-78,003
Closed -$6.85M – 126
2017
Q1 		$6.85M Buy
+78,003
New +$6.94M 0.92% 43
2016
Q4 		– Sell
-61,348
Closed -$5.68M – 137
2016
Q3 		$5.68M Buy
+61,348
New +$5.78M 0.78% 51

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Suffolk Capital Management's BMRN Position: Q2 2017 in Review

Suffolk Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 78,003 shares — an estimated $6.85M sold.

Suffolk Capital Management first reported a position in BMRN in Q3 2016 and held it in 2 quarters. The position peaked at $6.85M in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Suffolk Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 78,003 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $6.85M.
  • Suffolk Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Suffolk Capital Management's BioMarin Pharmaceuticals position peaked at $6.85M in Q1 2017.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Suffolk Capital Management's 13F filing for Q2 2017, filed 28 Jul 2017.